Jefferies analyst Peter Welford downgraded Roche to Hold from Buy with a price target of CHF 325, down from CHF 375.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on RHHBY:
- Roche downgraded to Underweight from Neutral at JPMorgan
- FDA approves Roche’s Lunsumio, a first-in-class bispecific antibody, to treat people with relapsed or refractory follicular lymphoma
- Genentech announces FDA approval of Lunsumio
- FDA approves Genentech’s Lunsumio in refractory follicular lymphoma
- FDA approves Roche’s Actemra for the treatment of COVID-19 in hospitalised adults